Plato Investment Management Ltd Acquires New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Plato Investment Management Ltd acquired a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 2nd quarter, Holdings Channel reports. The fund acquired 5,471 shares of the company’s stock, valued at approximately $43,000.

Several other large investors have also bought and sold shares of the business. Rubric Capital Management LP acquired a new stake in GoodRx in the fourth quarter valued at about $39,348,000. American Century Companies Inc. acquired a new stake in GoodRx in the second quarter valued at about $18,183,000. Rip Road Capital Partners LP boosted its stake in GoodRx by 25.8% in the fourth quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock valued at $11,814,000 after buying an additional 361,294 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in GoodRx by 24.3% in the second quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock valued at $4,736,000 after buying an additional 118,703 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of GoodRx during the first quarter valued at about $1,638,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on the company. UBS Group cut their price target on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Barclays lifted their price target on GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research note on Monday, May 20th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Morgan Stanley lifted their price target on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research note on Monday, June 10th. Finally, Citigroup cut their price target on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.36.

Insiders Place Their Bets

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.17% of the stock is currently owned by corporate insiders.

GoodRx Trading Down 0.9 %

Shares of GDRX stock opened at $7.68 on Tuesday. The company has a market cap of $2.88 billion, a P/E ratio of -768.00, a PEG ratio of 3.55 and a beta of 1.38. The stock has a 50 day simple moving average of $8.02 and a two-hundred day simple moving average of $7.61. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.02 earnings per share. Research analysts forecast that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.